Harvoni
ledispavir, sofosbuvir
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What Harvoni is and what it is used for
What you need to know before you take Harvoni
How to take Harvoni
Possible side effects
How to store Harvoni
Contents of the pack and other information
Harvoni is a medicine that contains the active substances ledipasvir and sofosbuvir. Harvoni is given to treat chronic (long-term) hepatitis C virus infection in adults and children 3 years of age and older.
Hepatitis C is a virus that infects the liver. The active substances in the medicine work together by blocking two different proteins that the virus needs to grow and reproduce itself, allowing the infection to be permanently eliminated from the body.
Harvoni is sometimes taken with another medicine, ribavirin.
It is very important that you also read the leaflets for the other medicines that you will be taking with Harvoni. If you have any questions about your medicines, please ask your doctor or pharmacist.
If any of these conditions apply to you, do not take Harvoni and tell your doctor immediately. Warnings and precautions
Your doctor will know if any of the following conditions apply to you. These will be considered before treatment with Harvoni is started.
Talk to your doctor or pharmacist before taking Harvoni if:
you currently take, or have taken in the last few months, the medicine amiodarone to treat irregular heartbeats, as it may result in a life-threatening slowing of your heart beat. Your doctor may consider different treatments if you have taken this medicine. If treatment with Harvoni is needed, you may require additional heart monitoring.
you have diabetes. You may need closer monitoring of your blood glucose levels and/or adjustment of your diabetes medication after starting Harvoni. Some diabetic patients have experienced low sugar levels in the blood (hypoglycaemia) after starting treatment with medicines like Harvoni.
slow or irregular heartbeat, or heart rhythm problems;
shortness of breath or worsening of existing shortness of breath;
chest-pain;
light-headedness
palpitations
near fainting or fainting
Your doctor will test your blood before, during and after your treatment with Harvoni. This is so that:
Your doctor can decide if you should take Harvoni and for how long;
Your doctor can confirm that your treatment has worked and you are free of the hepatitis C virus.
Do not give this medicine to children under 3 years of age. The use of Harvoni in children under 3 years of age has not yet been studied.
Warfarin and other similar medicines called vitamin K antagonists used to thin the blood. Your doctor may need to increase the frequency of your blood tests to check how well your blood can clot.
Your liver function may change with treatment of hepatitis C and therefore may affect other medications (e.g. medicines used to suppress your immune system, etc.). Your doctor may need to closely monitor these other medicines you are taking and make adjustments after starting Harvoni.
If you are not sure about taking any other medicines, talk to your doctor or pharmacist.
Taking Harvoni with any of these may stop your medicines from working properly, or make any side effects worse. Your doctor may need to give you a different medicine or adjust the dose of medicine you are taking.
antacids (such as aluminium/magnesium hydroxide or calcium carbonate). These should be taken at least 4 hours before or 4 hours after Harvoni;
proton pump inhibitors (such as omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole). These should be taken at the same time as Harvoni. Do not take proton pump inhibitors before Harvoni. Your doctor may give you a different medicine or adjust the dose of the medicine you are taking;
H2-receptor antagonists (such as famotidine, cimetidine, nizatidine or ranitidine). Your doctor may give you a different medicine or adjust the dose of the medicine you are taking.
These medicines can decrease the amount of ledipasvir in your blood. If you are taking one of these medicines your doctor will either give you a different medicine for stomach ulcers, heartburn or acid reflux, or recommend how and when you take that medicine.
The effects of Harvoni during pregnancy are not known. If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Pregnancy must be avoided if Harvoni is taken together with ribavirin. It is very important that you read the "Pregnancy" section in the ribavirin package leaflet very carefully. Ribavirin can be very damaging to an unborn baby. Therefore, special precautions in sexual activity must be taken if there is any chance for pregnancy to occur.
You or your partner must use an effective birth control method during treatment with Harvoni together with ribavirin and for some time afterwards. It is very important that you read the “Pregnancy” section in the ribavirin package leaflet very carefully. Ask your doctor for an effective contraceptive method suitable for you.
If you or your partner become pregnant during Harvoni and ribavirin treatment or in the months that follow, you must contact your doctor immediately.
If you feel tired after taking Harvoni you should not take part in activities that require concentration, for example, do not drive, ride a bike or operate machines.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Swallow the tablet(s) whole with or without food. Do not chew, crush or split the tablet as it has a very bitter taste. Tell your doctor or pharmacist if you have problems swallowing tablets.
If you are sick (vomit) less than 5 hours after taking Harvoni, take another dose.
If you are sick (vomit) more than 5 hours after taking Harvoni, you do not need to take another dose until your next scheduled dose.
If you accidentally take more than the recommended dose you should contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.
It is important not to miss a dose of this medicine.
If you do miss a dose, work out how long it is since you last took your Harvoni:
Do not stop taking this medicine unless your doctor tells you to. It is very important that you complete the full course of treatment to give the medicine the best chance to treat your hepatitis C virus infection.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects. If you take Harvoni you may get one or more of the side effects below:
(may affect more than 1 in 10 people)
headache
feeling tired
(may affect up to 1 in 10 people)
rash
The frequency of the following side effects is not known (frequency cannot be estimated from the available data).
swelling of the face, lips, tongue or throat (angioedema).
The frequency of the following side effects is not known (frequency cannot be estimated from the available data).
a wide-spread severe rash with peeling skin which may be accompanied by fever, flu-like symptoms, blisters in the mouth, eyes, and/or genitals (Stevens-Johnson syndrome).
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after “EXP”. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Harvoni contains
Tablet core:
Copovidone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate
Film-coating:
Polyvinyl alcohol, titanium dioxide, macrogol, talc, and for the 90 mg/400 mg tablet only; sunset yellow FCF (E110)
Harvoni 90 mg/400 mg film-coated tablets are orange, diamond-shaped tablets debossed with “GSI” on one side and “7985” on the other side. The tablet is approximately 19 mm long and 10 mm wide.
Harvoni 45 mg/200 mg film-coated tablets are white, capsule-shaped, debossed with “GSI” on one side and “HRV” on the other side. The tablet is approximately 14 mm long and 7 mm wide.
Each bottle contains a silica gel desiccant (drying agent) that must be kept in the bottle to help protect your tablets. The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
The following pack sizes are available:
outer cartons containing 1 bottle of 28 film-coated tablets for the 90 mg/400 mg and the 45 mg/ 200 mg film-coated tablets.
outer cartons containing 3 bottles of 28 (84) film-coated tablets for the 90 mg/400 mg film-coated tablets only. Not all pack sizes may be marketed.
County Cork, T45 DP77 Ireland
Gilead Sciences Ireland UC
IDA Business & Technology Park Carrigtohill
County Cork Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Gilead Sciences Belgium SRL-BV Tél/Tel: + 32 (0) 24 01 35 50
Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702
Gilead Sciences Ireland UC
Тел.: + 353 (0) 1 686 1888
Gilead Sciences Belgium SRL-BV Tél/Tel: + 32 (0) 24 01 35 50
Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888
Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849
Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888
Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0
Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98
Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702
Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849
Gilead Sciences Ελλάς Μ.ΕΠΕ. Τηλ: + 30 210 8930 100
Gilead Sciences GesmbH Tel: + 43 1 260 830
Gilead Sciences, S.L. Tel: + 34 91 378 98 30
Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702
Gilead Sciences
Tél: + 33 (0) 1 46 09 41 00
Gilead Sciences, Lda. Tel: + 351 21 7928790
Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888
Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888
Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 999
Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888
Gilead Sciences Sweden AB Sími: + 46 (0) 8 5057 1849
Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 210
Gilead Sciences S.r.l. Tel: + 39 02 439201
Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849
Gilead Sciences Ελλάς Μ.ΕΠΕ. Τηλ: + 30 210 8930 100
Sverige
Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849
Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702
Gilead Sciences Ireland UC Tel: + 44 (0) 8000 113700